Boehringer Ingelheim appoints Marcelo Dotti Ratti Country Manager, Colombia
Boehringer Ingelheim designa a Marcelo Dotti Ratti Gerente General para Colombia
Intel ID : 409480
|
||||
| Intel ID | 409480 | |||
| Value | ND | |||
| Native Currency |
Colombian Peso (COP)
Exchange Rate:  |
|||
|
Financial Data - Boehringer Ingelheim
(31 Dec 2024) |
Revenue: EUR 253,87m Net Debt: EUR 24,01m Exchange Rate: 
|
|||
| Date |
|
|||
| Country | |
|||
| Geography | |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Secondary Subsectors (TTRSC) |
55.02.04 Pharmaceutical & Personal Care Chemicals 55 Raw Materials & Natural Resources / 55.02 Chemicals 30.03.99 Other Healthcare Facilities & Services 30 Healthcare / 30.03 Healthcare Facilities & Services |
|||
| Type |
|
|||
| Intel Grade |
|
|||
| Source |
|
|||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Related Entity
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.03.99 Other Healthcare Facilities & Services 30 Healthcare / 30.03 Healthcare Facilities & Services 55.02.04 Pharmaceutical & Personal Care Chemicals 55 Raw Materials & Natural Resources / 55.02 Chemicals |
||
| Country |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.